Compare · IART vs MDLN
IART vs MDLN
Side-by-side comparison of Integra LifeSciences Holdings Corporation (IART) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IART and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $54.01B, about 35.0x IART ($1.54B).
- Over the past year, IART is up 60.6% and MDLN is down 2.3% - IART leads by 62.9 points.
- IART has been more active in the news (9 items in the past 4 weeks vs 4 for MDLN).
- Both have 25 recent analyst ratings on file.
- Company
- Integra LifeSciences Holdings Corporation
- Medline Inc.
- Price
- $19.24-3.15%
- $39.80-3.23%
- Market cap
- $1.54B
- $54.01B
- 1M return
- +8.73%
- +7.36%
- 1Y return
- +60.60%
- -2.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 25
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Latest IART
- Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
- BMO Capital Markets initiated coverage on Integra with a new price target
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 937 shares, decreasing direct ownership by 3% to 34,516 units (SEC Form 4)
- SEC Form 4 filed by EVP & President, SS Singh Harvinder
- SEC Form 4 filed by EVP & President, TR&DT Davis Robert T. Jr.
- EVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 5,226 shares, decreasing direct ownership by 10% to 45,263 units (SEC Form 4)
- Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
- Integra LifeSciences Announces Key Executive Appointments
- Integra upgraded by Argus with a new price target
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)